Pacific Biosciences of California, Inc. Announces Third Quarter 2017 Financial Results
Nov 02, 2017 20:01 pm UTC| Business
MENLO PARK, Calif., Nov. 02, 2017 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its third quarter ended September 30, 2017. Product, service and other revenue for the...
Accelerate Diagnostics reports Q3 2017 financial results
Nov 02, 2017 20:01 pm UTC| Business
TUCSON, Ariz., Nov. 02, 2017 -- Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending September 30, 2017. The company further reported signed agreements for 295 instruments...
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights
Nov 02, 2017 20:01 pm UTC| Business
VY-AADC for advanced Parkinson’s disease on track for start of global, pivotal phase 2-3 program Integration of novel capsid and delivery optimization efforts expected to result in two IND filings from the ALS,...
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results
Nov 02, 2017 20:01 pm UTC| Business
Vitaros U.S. NDA Resubmission Review Remains on TrackPDUFA Goal Date of February 17, 2018 Conference Call / Webcast Today, November 2, 2017 at 4:30 p.m. ET SAN DIEGO, Calif., Nov. 02, 2017 -- Apricus Biosciences,...
Sportsman's Warehouse Holdings, Inc. Announces Third Quarter 2017 Earnings Conference Call
Nov 02, 2017 20:01 pm UTC| Business
MIDVALE, Utah, Nov. 02, 2017 -- Sportsman's Warehouse Holdings, Inc. ("Sportsman's" or the "Company") (Nasdaq:SPWH) today announced that it will hold its quarterly conference call to discuss third quarter 2017 financial...
Cara Therapeutics Reports Third Quarter 2017 Financial Results
Nov 02, 2017 20:01 pm UTC| Business
STAMFORD, Conn., Nov. 02, 2017 -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively...
Nov 02, 2017 20:01 pm UTC| Business
First full quarter of TYMLOS™ sales shows accelerating market share stabilization of the anabolic market Plan access at approximately 200 million lives – 87% commercial and 35% Medicare Male Osteo Trial: FDA agreement...